FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886637474> ?p ?o ?g. }

• W2886637474 endingPage "381" @default.
• W2886637474 startingPage "373" @default.
• W2886637474 abstract "Dyskinesia is a common motor complication associated with the use of levodopa to treat Parkinson's disease. Numerous animal studies in mice, rats, and nonhuman primates have demonstrated that the N-methyl-d-aspartate antagonist, amantadine, dose dependently reduces levodopa-induced dyskinesia (LID). However, none of these studies characterized the amantadine plasma concentrations required for a therapeutic effect. This study evaluates the pharmacokinetic (PK)/pharmacodynamic (PD) relationship between amantadine plasma concentrations and antidyskinetic efficacy across multiple species to define optimal therapeutic dosing. The PK profile of amantadine was determined in mice, rats, and macaques. Efficacy data from the 6-hydroxydopamine rat and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque model of LID, along with previously published antidyskinetic efficacy data, were used to establish species-specific PK/PD relationships using a direct-effect maximum possible effect model. Results from the PK/PD model were compared with amantadine plasma concentrations and antidyskinetic effect in a phase 2 study in patients with Parkinson's disease treated with ADS-5102, an extended-release amantadine capsule formulation. Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model). These data are consistent with the mean amantadine plasma concentrations observed in patients with Parkinson's disease (∼1500 ng/ml) treated with ADS-5102 at doses that demonstrated a statistically significant reduction in dyskinesia. These results demonstrate that the EC50 of amantadine for reducing dyskinesia is consistent across multiple species and supports a plasma concentration target of ∼1400 ng/ml to achieve therapeutic efficacy." @default.
• W2886637474 created "2018-08-22" @default.
• W2886637474 creator A5018228116 @default.
• W2886637474 creator A5035204197 @default.
• W2886637474 creator A5042941039 @default.
• W2886637474 creator A5044200001 @default.
• W2886637474 creator A5048325113 @default.
• W2886637474 creator A5048688457 @default.
• W2886637474 creator A5070056743 @default.
• W2886637474 creator A5070515921 @default.
• W2886637474 creator A5089076582 @default.
• W2886637474 date "2018-08-07" @default.
• W2886637474 modified "2023-09-26" @default.
• W2886637474 title "Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia" @default.
• W2886637474 cites W1569799839 @default.
• W2886637474 cites W1571001168 @default.
• W2886637474 cites W1585430153 @default.
• W2886637474 cites W1727176495 @default.
• W2886637474 cites W1926423117 @default.
• W2886637474 cites W1976836813 @default.
• W2886637474 cites W1986017124 @default.
• W2886637474 cites W1994109837 @default.
• W2886637474 cites W1998649401 @default.
• W2886637474 cites W2007037518 @default.
• W2886637474 cites W2011503760 @default.
• W2886637474 cites W2020789218 @default.
• W2886637474 cites W2025102930 @default.
• W2886637474 cites W2035779111 @default.
• W2886637474 cites W2044069219 @default.
• W2886637474 cites W2055680935 @default.
• W2886637474 cites W2068446033 @default.
• W2886637474 cites W2082985298 @default.
• W2886637474 cites W2083229883 @default.
• W2886637474 cites W2093256000 @default.
• W2886637474 cites W2093755310 @default.
• W2886637474 cites W2112391315 @default.
• W2886637474 cites W2113826471 @default.
• W2886637474 cites W2115222037 @default.
• W2886637474 cites W2127460561 @default.
• W2886637474 cites W2132008514 @default.
• W2886637474 cites W2133527428 @default.
• W2886637474 cites W2143384631 @default.
• W2886637474 cites W2314577195 @default.
• W2886637474 cites W2509149624 @default.
• W2886637474 cites W2621548695 @default.
• W2886637474 cites W2747038847 @default.
• W2886637474 cites W2804952730 @default.
• W2886637474 doi "https://doi.org/10.1124/jpet.118.247650" @default.
• W2886637474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30087157" @default.
• W2886637474 hasPublicationYear "2018" @default.
• W2886637474 type Work @default.
• W2886637474 sameAs 2886637474 @default.
• W2886637474 citedByCount "21" @default.
• W2886637474 countsByYear W28866374742018 @default.
• W2886637474 countsByYear W28866374742019 @default.
• W2886637474 countsByYear W28866374742020 @default.
• W2886637474 countsByYear W28866374742021 @default.
• W2886637474 countsByYear W28866374742022 @default.
• W2886637474 countsByYear W28866374742023 @default.
• W2886637474 crossrefType "journal-article" @default.
• W2886637474 hasAuthorship W2886637474A5018228116 @default.
• W2886637474 hasAuthorship W2886637474A5035204197 @default.
• W2886637474 hasAuthorship W2886637474A5042941039 @default.
• W2886637474 hasAuthorship W2886637474A5044200001 @default.
• W2886637474 hasAuthorship W2886637474A5048325113 @default.
• W2886637474 hasAuthorship W2886637474A5048688457 @default.
• W2886637474 hasAuthorship W2886637474A5070056743 @default.
• W2886637474 hasAuthorship W2886637474A5070515921 @default.
• W2886637474 hasAuthorship W2886637474A5089076582 @default.
• W2886637474 hasBestOaLocation W28866374741 @default.
• W2886637474 hasConcept C111113717 @default.
• W2886637474 hasConcept C112705442 @default.
• W2886637474 hasConcept C126322002 @default.
• W2886637474 hasConcept C181389837 @default.
• W2886637474 hasConcept C2776525014 @default.
• W2886637474 hasConcept C2777374534 @default.
• W2886637474 hasConcept C2779134260 @default.
• W2886637474 hasConcept C2779734285 @default.
• W2886637474 hasConcept C2780304432 @default.
• W2886637474 hasConcept C2780405171 @default.
• W2886637474 hasConcept C71924100 @default.
• W2886637474 hasConcept C98274493 @default.
• W2886637474 hasConceptScore W2886637474C111113717 @default.
• W2886637474 hasConceptScore W2886637474C112705442 @default.
• W2886637474 hasConceptScore W2886637474C126322002 @default.
• W2886637474 hasConceptScore W2886637474C181389837 @default.
• W2886637474 hasConceptScore W2886637474C2776525014 @default.
• W2886637474 hasConceptScore W2886637474C2777374534 @default.
• W2886637474 hasConceptScore W2886637474C2779134260 @default.
• W2886637474 hasConceptScore W2886637474C2779734285 @default.
• W2886637474 hasConceptScore W2886637474C2780304432 @default.
• W2886637474 hasConceptScore W2886637474C2780405171 @default.
• W2886637474 hasConceptScore W2886637474C71924100 @default.
• W2886637474 hasConceptScore W2886637474C98274493 @default.
• W2886637474 hasIssue "2" @default.
• W2886637474 hasLocation W28866374741 @default.
• W2886637474 hasLocation W28866374742 @default.
• W2886637474 hasOpenAccess W2886637474 @default.

• next